Related references
Note: Only part of the references are listed.Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer
Stefanie Gross et al.
IMMUNOLOGY LETTERS (2008)
The international harmonization project for response criteria in lymphoma clinical trials
Bruce D. Cheson
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
Christian Brandl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Update on anti-CTLA-4 antibodies in clinical trials
Lee F. Langer et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Phenotypic characterization of human colorectal cancer stem cells
Piero Dalerba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct
Scott A. Hammond et al.
CANCER RESEARCH (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
B Schlereth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers
P Went et al.
BRITISH JOURNAL OF CANCER (2006)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
B Schlereth et al.
CANCER RESEARCH (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High frequency of functionally active Melan-A-specific T cells in a patient with progressive immunoproteasome-deficient melanoma
N Meidenbauer et al.
CANCER RESEARCH (2004)
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
A Löffler et al.
LEUKEMIA (2003)
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
T Dreier et al.
JOURNAL OF IMMUNOLOGY (2003)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
T Dreier et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
